In 40 younger AML patients (<60 years) midostaurin plus IC provided an overall CR rate of 80% [90% in FLT3-ITD, 74% in FLT3-wild type (WT)] but had no impact on OS [35]. Here, FLT3 is linked to acute myeloid leukemia.